Biontech Se Sponsored Adr Stock News

ADRs Close Lower; BioNTech Rises, Carnival Drops Morningstar.com

Pfizer and BioNTech announced on Friday that its COVID-19 vaccine could be reworked in approximately 100 days to counter a new variant of the CCP virus that may be able to penetrate through vaccines. The U.S.-based pharmaceutical company said in a statement obtained by news agency Reuters it expects more data on B.1.1.529, the new variant []

Bengaluru: Karnataka Chief Minister Basavaraj Bommai called a meeting on Saturday evening to review the situation that has arisen as a result of an increase in Covid-19 cases in Bengaluru and Dharwad, as well as the impact of the new strain of the virus. At 4 p.m., a conference will be held to discuss if the virus is spreading from Kerala, which is seeing an increase in Covid cases, as well as preventative measures. Bommai noted that authorities from the Department of Health, the Disaster Management and Advisory Board on Covid-19, as well as experts, will convene to consider the next steps. He urged the people to join the Health Department in taking efforts to prevent the dangerous illness from spreading. K. Sudhakar, the Minister of Health, declared that the new virus should not be a cause for alarm. New rules will be issued, and airports will conduct Covid testing, with individuals who test positive being quarantined. After a week, they will be submitted to another test, he added. The Chief Minister noted that the symptoms of the new Covid strain Omicron are similar to those of previous strains.

Stocks sold off sharply on Black Friday with concerns over a new Covid variant adding to macro uncertainties. The potential for new travel restrictions or return of social distancing measures represen

BioNTech SE said on Friday it expects more data on a worrying new coronavirus variant detected in South Africa within two weeks to help determine whether its vaccine produced with partner Pfizer Inc would have to be reworked. Gloria Tso reports.

Work is underway to look at tweaking vaccines against the new concerning strain of coronavirus that has sparked travel bans. The variant, named Omicron

Biontech says it expects to have more data within two weeks to help determine whether the coronavirus vaccine, which it co-developed with Pfizer, needs to be reworked because of a new version of the coronavirus discovered in South Africa. Pfizer and Biontech have said they expect to be able to deliver a possible new vaccine made for the new version in about 100 days, if necessary. "We expect new data from laboratory tests within two weeks at the latest," they said. Moderna said it was working on a new version of its covid vaccine for the new strain, also called Omicron. The company added that it intends to test the possibility of a higher dosage of its already administered booster vaccine for better results against the new strain. Moderna said it would study other candidates for a booster vaccine to protect against new mutations in the virus, such as Omicron. /BTA

FRANKFURT (REUTERS) BioNTech said on Friday (Nov 26) it expects more data on a worrying new coronavirus variant detected in South Africa within 2 weeks to help determine whether its The post Pfizer and BioNTech expect data on shots protection against new Covid-19 variant soon appeared first on Nigeria''s Top News Site .

November 27, 2021 11:43 AM If necessary they expect to ship a vaccine tailored to the new variant in about 100 days.

The pharmaceutical companies underscored that they started working on making their vaccine adaptable to new possible variants months ago.

NEW YORK: Oil prices plunged $10 a barrel on Friday, their largest one-day drop since April 2020, as a new variant of the coronavirus spooked investors and added to concerns that a supply surplus could swell in the first quarter. Oil fell with global equities markets on fears the variant, could dampen economic growth and fuel demand. The World Health Organization has designated the new variant, which it named Omicron, as of concern, according to the South African health minister. The United States, Canada, Britain, Guatemala and European countries are among those to restrict travel from southern Africa, where the variant was detected. Brent crude settled down $9.50, or 11.6%, to $72.72 a barrel, a weekly decline of more than 8%. U.S. West Texas Intermediate (WTI) crude settled down $10.24 on Friday, or 13.1%, at $68.15 a barrel, declining more than 10.4% on the week in high volume trading after Thursdays Thanksgiving holiday in the United States. The market is factoring in a worst case scenario situation in which this variant causes massive demand destruction, said Bob Yawger, director of energy futures at Mizuho.

Pfizer and BioNTech said that if necessary they expect to be able to ship a new vaccine tailored to the emerging variant in approximately 100 days.

26 More Cases Of Heart Inflammation Linked To Pfizer Jab Pfizer is already quietly scrambling Friday as the COVID "variant of the moment" raises new questions about the efficacy of its vaccine (while the latest "data" shows Merck may have oversold its mulnupiravir drug as a "miracle cure" for the virus), it appears 26 new cases of the rare side effect known as myocarditis have been reported during the week ending Nov. 21. There is also one new case of blood clots case linked to the AstraZeneca jab following receipt of the first dose. The new case increased the total Thrombosis with thrombocytopenia syndrome (TTS) or blood clots cases to 164 out of 13.4 million doses. Of these 148 (81 confirmed, 62 probable) related to a first dose of and 21 to a second dose (six confirmed, 15 probable). Eight people have died as a result of blood clots six of these were women. Put another way, myocarditis is reported in one to two in every 100,000 people who receive Pfizer. There have also been a total of 150 reports of suspected Guillain-Barre Syndrome (GBS) occurring after vaccination with AstraZeneca, a rare but sometimes serious immune disorder affecting the nerves.

FinancialBuzz.coms latest The Buzz Show: Featuring Our Corporate News Recap on BioNTech SE Surges after it and Pfizer Inc. Received Positive CHMP Opinion for Comirnaty in Children ages 5-12 BioNTech SE (NASDAQ: BNTX) climbed over 10% in premarket trading after the company and Pfizer Inc. received a positive CHMP Opinion on the administration of COMIRNATY® The post The Buzz Show: BioNTech SE (NASDAQ: BNTX) and Pfizer Receive Positive CHMP Opinion for Comirnaty first appeared on Financial Buzz .

During the recent session, BioNTech SE (NASDAQ:BNTX)s traded shares were 6.69 million. At the last check today, the stocks price was $366.67, reflecting an intraday gain of 20.31% or $61.91. The 52-week high for the BNTX share is $464.00, that puts it down -26.54 from that peak though still a striking 78.03% gain since the Is BioNTech SE (NASDAQ: BNTX) Stock On Course For Another Boom Or Bust? Read More »